Stocktoria
BIOMERICA INC BMRA
Nasdaq · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 1980-03-17
BIOMERICA INC financials (annual)
Bars are annual figures from 2017 to 2026; red bars are negative (a loss or cash outflow).
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.5M | $5.3M | $5.4M | $5.3M | $18.9M | $7.2M | $6.7M | $5.2M | $5.6M | $5.8M |
| Gross profit | $362,000 | $498,000 | $611,000 | $446,000 | $3.0M | $366,285 | $1.8M | $1.3M | $1.8M | $2.0M |
| R&D expense | $788,000 | $1.0M | $1.5M | $1.6M | $1.8M | $2.2M | $1.9M | $1.7M | $1.4M | $1.1M |
| SG&A expense | $4.9M | $4.6M | $5.5M | $6.1M | $5.7M | $5.7M | $2.3M | $2.0M | $1.8M | $1.8M |
| Operating income | -$5.3M | -$5.1M | -$6.4M | -$7.2M | -$4.5M | -$7.5M | -$2.4M | -$2.4M | -$1.5M | -$954,633 |
| Interest expense | — | — | — | — | — | $367 | $9 | $47 | $37 | $282 |
| Income tax | $23,000 | $1,000 | $42,000 | $51,000 | $24,000 | $13,057 | $7,390 | $24,237 | $31,800 | — |
| Net income | -$3.8M | -$5.0M | -$6.0M | -$7.1M | -$4.5M | -$7.4M | -$2.3M | -$2.4M | -$1.5M | -$908,561 |
| EPS (diluted) | $-1.30 | $-2.16 | $-2.84 | $-0.50 | $-0.36 | $-0.62 | $-0.23 | $-0.26 | $-0.17 | $-0.11 |
| Operating cash flow | -$3.4M | -$3.8M | -$5.4M | -$5.5M | -$479,000 | -$5.3M | -$4.3M | -$2.2M | -$1.2M | -$722,858 |
| Free cash flow | — | — | -$5.4M | -$5.5M | -$536,000 | -$5.4M | -$4.3M | -$2.3M | -$1.3M | -$818,943 |
| Cash & equivalents | $1.3M | $2.4M | $4.2M | $9.7M | $5.9M | $4.2M | $8.6M | $686,785 | $1.2M | $1.2M |
| Inventory | $1.7M | $1.5M | $2.4M | $2.1M | $2.4M | $3.2M | $2.9M | $2.2M | $2.2M | $1.7M |
| Total assets | $6.8M | $5.9M | $9.3M | $14.5M | $11.4M | $11.8M | $17.3M | $5.2M | $5.2M | $5.0M |
| Total liabilities | $4.1M | $1.8M | $2.7M | $2.7M | $3.0M | $2.6M | $3.0M | $1.3M | — | — |
| Shareholders' equity | $2.6M | $4.1M | $6.6M | $11.7M | $8.3M | $9.2M | $14.2M | $4.0M | $4.3M | $4.5M |
Growth · year-over-year · Revenue CAGR -2.9%
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -16.2% | -1.9% | +1.4% | -71.7% | +162.1% | +7.6% | +28.7% | -6.5% | -3.9% | +12.7% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-05-31. Facts plus Stocktoria's own computed scores — not investment advice.